Clinical, biological, and pharmacological exploration of a NEDD4-2 polymorphism in healthy volunteers

Phase 4, single-arm trial of amiloride, desmopressin, potassium chloride and potassium glycerophosphate, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Primary endpoint: acute and chronic renin-angiotensin system readjustment, Primary objective: association between NEDD4-2 genetic variation and dietary adaptation and 1 more. Started Jan 2007; status: completed.